{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T06:08:01Z","timestamp":1761718081283},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[2005,1,1]],"date-time":"2005-01-01T00:00:00Z","timestamp":1104537600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Bone Miner Metab"],"published-print":{"date-parts":[[2005,1]]},"DOI":"10.1007\/bf03026333","type":"journal-article","created":{"date-parts":[[2009,1,13]],"date-time":"2009-01-13T02:09:34Z","timestamp":1231812574000},"page":"103-108","source":"Crossref","is-referenced-by-count":4,"title":["Biopolymer-based delivery systems for advanced imaging and skeletal tissue-specific therapeutics"],"prefix":"10.1007","volume":"23","author":[{"given":"Scott C.","family":"Miller","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pavla","family":"Kope\u010dkov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jind\u0159ich","family":"Kope\u010dek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"BF03026333_CR1","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0939-6411(00)00075-8","volume":"50","author":"J Kope\u010dek","year":"2000","unstructured":"Kope\u010dek J, Kope\u010dkov\u00e1 P, Minko T, Lu ZR (2000) HPMA copolymer-anticancer drug conjugates: design, activity, and mechanism of action. Eur J Pharm Biopharm 50: 61\u201381","journal-title":"Eur J Pharm Biopharm"},{"key":"BF03026333_CR2","doi-asserted-by":"crossref","first-page":"36993","DOI":"10.1074\/jbc.M105854200","volume":"276","author":"KR Kozak","year":"2001","unstructured":"Kozak KR, Crews BC, Ray JL, Tai HH, Morrow JD, Marnett LJ (2001) Metabolism of prostaglandin glycerol esters and prostaglandin ethanolamides in vitro and in vivo. J Biol Chem 276: 36993\u201336998","journal-title":"J Biol Chem"},{"key":"BF03026333_CR3","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/S0960-894X(01)80365-6","volume":"4","author":"MW Orme","year":"1994","unstructured":"Orme MW, Labroo VM (1994) Synthesis of \u03b1-estradiol-3- benzoate-17-(succinyl-12a-tetracycline): a potential bone-seeking estrogen. Bioorg Med Chem Lett 4: 1375\u20131380","journal-title":"Bioorg Med Chem Lett"},{"key":"BF03026333_CR4","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/0960-894X(96)00164-3","volume":"6","author":"TM Wilson","year":"1996","unstructured":"Wilson TM, Charifson PS, Baxter AD, Geddie NG (1996) Bonetargeted drugs. 1. Indentification of heterocycles with hydroxyapatite affinity. Bioorg Med Chem Lett 6: 1043\u20131046","journal-title":"Bioorg Med Chem Lett"},{"key":"BF03026333_CR5","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1021\/bp0200447","volume":"18","author":"H Uludag","year":"2002","unstructured":"Uludag H, Yang J (2002) Targeting systemically administered proteins to bone by bisphosphonate conjugation. Biotechnol Prog 18: 604\u2013611","journal-title":"Biotechnol Prog"},{"key":"BF03026333_CR6","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1359\/jbmr.2000.15.5.936","volume":"15","author":"S Kasugai","year":"2000","unstructured":"Kasugai S, Fujisawa R, Waki Y, Miyamoto K-I, Ohya K (2000) Selective drug delivery system to bone: small peptide (Asp)6 conjugation. J Bone Miner Res 15: 936\u2013943","journal-title":"J Bone Miner Res"},{"key":"BF03026333_CR7","first-page":"135","volume":"9","author":"LW Seymour","year":"1992","unstructured":"Seymour LW (1992) Passive tumor targeting of soluble macromolecules and drug conjugates. Crit Rev Ther Drug Carrier Syst 9: 135\u2013187","journal-title":"Crit Rev Ther Drug Carrier Syst"},{"key":"BF03026333_CR8","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1021\/bc034090j","volume":"14","author":"D Wang","year":"2003","unstructured":"Wang D, Miller SC, Sima M, Kope\u010dkov\u00e1 P, Kope\u010dek J (2003) Synthesis and evaluation of water-soluble polymeric bone-targeted drug delivery systems. Bioconjug Chem 14: 853\u2013859","journal-title":"Bioconjug Chem"},{"key":"BF03026333_CR9","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/0014-3057(73)90063-3","volume":"9","author":"J Kope\u010dek","year":"1973","unstructured":"Kope\u010dek J, Ba\u0161ilov\u00e1 H (1973) Poly(N-(2-hydroxypropyl) methacrylamide). I. Radical polymerization and copolymerization. Eur Polym J 9: 7\u201314","journal-title":"Eur Polym J"},{"key":"BF03026333_CR10","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1023\/B:PHAM.0000045232.18134.e9","volume":"21","author":"D Wang","year":"2004","unstructured":"Wang D, Miller SC, Sima M, Parker D, Buswell H, Goodrich KC, Kope\u010dkova P, Kope\u010dek J (2004) The arthrotropism of macromolecules in adjuvant induced arthritis rat model: a preliminary study. Pharm Res 21: 1741\u20131749","journal-title":"Pharm Res"},{"key":"BF03026333_CR11","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1002\/jbm.820211106","volume":"21","author":"LW Seymour","year":"1987","unstructured":"Seymour LW, Duncan R, Strohalm J, Kope\u010dek J (1987) Effect of molecular weight (MW) ofN-(2-hydroxypropyl)methacrylamide copolymers on body distribution and rate of excretion after subcutaneous, intraperitoneal, and intravenous administration to rats. J Biomed Mater Res 21: 1341\u20131358","journal-title":"J Biomed Mater Res"},{"key":"BF03026333_CR12","first-page":"377","volume":"1","author":"AM Bendele","year":"2001","unstructured":"Bendele AM (2001) Animal models of rheumatoid arthritis. J Musculoskel Neuron Interact 1: 377\u2013385","journal-title":"J Musculoskel Neuron Interact"},{"key":"BF03026333_CR13","doi-asserted-by":"crossref","first-page":"8447","DOI":"10.1021\/bi025638x","volume":"41","author":"F Lecaille","year":"2002","unstructured":"Lecaille F, Choe Y, Brandt W, Li Z, Craik CS, Br\u00f6mme D (2002) Selective inhibition of the collagenolytic activity of human cathepsin K by altering its S2 subsite specificity. Biochemistry 41: 8447\u20138454","journal-title":"Biochemistry"},{"key":"BF03026333_CR14","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1210\/endo.142.3.8024","volume":"142","author":"K Yokogawa","year":"2001","unstructured":"Yokogawa K, Miya K, Sekido T, Higashi Y, Nomura M, Fujisawa R, Morito K, Masamune Y, Waki Y, Kasugai S, Miyamoto K-I (2001) Selective delivery of estradiol to bone by aspartic acid oligopeptide and its effects on ovariectomized mice. Endocrinology 142: 1228\u20131233","journal-title":"Endocrinology"},{"key":"BF03026333_CR15","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S0968-0896(99)00045-0","volume":"7","author":"L Gil","year":"1999","unstructured":"Gil L, Han Y, Opas EE, Rodan GA, Ruel R, Seedor JG, Tyler PC, Young RN (1999) Prostaglandin E2-bisphosphonate conjugates: potential agents for treatment of osteoporosis. Bioorg Med Chem 7: 901\u2013919","journal-title":"Bioorg Med Chem"},{"key":"BF03026333_CR16","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1002\/art.1780140503","volume":"14","author":"I Kushner","year":"1971","unstructured":"Kushner I, Somerville JA (1971) Permeability of human synovial membrane to plasma proteins. Relationship to molecular size and inflammation. Arthritis Rheum 14: 560\u2013570","journal-title":"Arthritis Rheum"},{"key":"BF03026333_CR17","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1002\/art.1780300108","volume":"30","author":"WJ Wallis","year":"1987","unstructured":"Wallis WJ, Simkin PA, Nelp WB (1987) Protein traffic in human synovial effusion. Arthritis Rheum 30: 57\u201363","journal-title":"Arthritis Rheum"},{"key":"BF03026333_CR18","first-page":"1008","volume":"6","author":"JG Shiah","year":"2000","unstructured":"Shiah JG, Sun Y, Peterson CM, Straight RC, Kopecek J (2000) Antitumor activity ofN-(2-hydroxypropyl)methacrylamide copolymer-mesochlorin e6 and adriamycin conjugates in combination treatments. Clin Cancer Res 6: 1008\u20131015","journal-title":"Clin Cancer Res"},{"key":"BF03026333_CR19","first-page":"6387","volume":"46","author":"Y Matsumura","year":"1986","unstructured":"Matsumura Y, Maeda H (1986) A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 46: 6387\u20136392","journal-title":"Cancer Res"},{"key":"BF03026333_CR20","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1002\/jbm.820100612","volume":"10","author":"L \u0160princl","year":"1976","unstructured":"\u0160princl L, Exner J, \u0160t\u011brba O, Kope\u010dek J (1976) New types of synthetic infusion solutions. III. Elimination and retention of poly(N-(2-hydroxypropyl)methacrylamide) in a test organism. J Biomed Mater Res 10: 953\u2013963","journal-title":"J Biomed Mater Res"},{"key":"BF03026333_CR21","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/0142-9612(84)90048-6","volume":"5","author":"B \u0158\u00edhov\u00e1","year":"1984","unstructured":"\u0158\u00edhov\u00e1 B, Kope\u010dek J, Ulbrich K, Posp\u00ed\u0161il J, Man\u010dai P (1984) Effect of the chemical structure ofN-(2-hydroxypropyl)methacrylamide copolymers on their ability to induce antibody formation in inbred strains of mice. Biomaterials 5: 143\u2013148","journal-title":"Biomaterials"},{"key":"BF03026333_CR22","first-page":"83","volume":"5","author":"PA Vasey","year":"1999","unstructured":"Vasey PA, Kaye SB, Morrison R, Twelves C, Wilson P, Duncan R Thomson AH, Murray LS, Hilditch TE, Murray T, Burtles S, Fraier D, Frigeiro E, Cassidy J (1999) Phase I clinical and pharmacokinetic study of PK1 (N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin): first member of a new class of chemotherapeutic agents \u2014 drug-polymer conjugates. Clin Cancer Res 5: 83\u201394","journal-title":"Clin Cancer Res"},{"key":"BF03026333_CR23","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1200\/JCO.2002.20.6.1668","volume":"20","author":"LW Seymour","year":"2002","unstructured":"Seymour LW, Ferry DR, Anderson D, Hesselwood S, Julyan PL, Poyner R, Doran J, Young AM, Burtless S, Kerr DJ (2002) Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin. J Clin Oncol 20: 1668\u20131676","journal-title":"J Clin Oncol"}],"container-title":["Journal of Bone and Mineral Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03026333.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF03026333\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03026333","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,22]],"date-time":"2019-05-22T20:27:44Z","timestamp":1558556864000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF03026333"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,1]]},"references-count":23,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2005,1]]}},"alternative-id":["BF03026333"],"URL":"https:\/\/doi.org\/10.1007\/bf03026333","relation":{},"ISSN":["0914-8779","1435-5604"],"issn-type":[{"value":"0914-8779","type":"print"},{"value":"1435-5604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,1]]}}}